5 Best High Risk High Reward Stocks To Buy Now

3. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Number of Hedge Fund Investors In Q2 2023: 33

Latest P/S Ratio: 4,890

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) develops immune system drugs that enable it to fight cancer. It reported $238,000 in revenue for its second quarter, a significant improvement over the year ago quarter’s results since back then the revenue was $0.

After scouring through 910 hedge fund portfolios for 2023’s second quarter, Insider Monkey discovered 33 investors in the firm. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s largest shareholder is Joseph Edelman’s Perceptive Advisors since it owns 14 million shares that are worth $98.8 million.

Follow Iovance Biotherapeutics Inc. (NASDAQ:IOVA)